EirGenix, Inc.

EirGenix is a leading biopharmaceutical company based in Taiwan, operating as both a Contract Development and Manufacturing Organization (CDMO) and a developer of proprietary biologics and biosimilars. The company provides end-to-end services including cell line development, process development, and large-scale cGMP manufacturing for mammalian and microbial systems. EirGenix is strategically focused on the oncology market, particularly HER2-targeted therapies. Its dual-business model leverages its CDMO expertise to fund and accelerate its internal pipeline of biosimilars and antibody-drug conjugates (ADCs). The company maintains state-of-the-art facilities in Xizhi and Zhubei, Taiwan, and has established significant global partnerships, most notably with Sandoz for the commercialization of its lead biosimilar assets.